MX2021009344A - Composiciones con aminoacidos para el uso y tratamiento de lesiones del sistema nervioso central. - Google Patents
Composiciones con aminoacidos para el uso y tratamiento de lesiones del sistema nervioso central.Info
- Publication number
- MX2021009344A MX2021009344A MX2021009344A MX2021009344A MX2021009344A MX 2021009344 A MX2021009344 A MX 2021009344A MX 2021009344 A MX2021009344 A MX 2021009344A MX 2021009344 A MX2021009344 A MX 2021009344A MX 2021009344 A MX2021009344 A MX 2021009344A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- amino acids
- nervous system
- central nervous
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000001413 amino acids Chemical class 0.000 title abstract 2
- 208000001738 Nervous System Trauma Diseases 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 title 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 abstract 1
- 150000001735 carboxylic acids Chemical class 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 239000001630 malic acid Substances 0.000 abstract 1
- 235000011090 malic acid Nutrition 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composición para uso en el tratamiento de una enfermedad del sistema nervioso central, la composición comprende un agente activo, dicho agente activo contiene los aminoácidos leucina, isoleucina, valina, treonina, lisina y los ácidos carboxílicos ácido cítrico, ácido succínico, ácido málico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102019000002109A IT201900002109A1 (it) | 2019-02-13 | 2019-02-13 | Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale |
| PCT/IB2020/051027 WO2020165731A1 (en) | 2019-02-13 | 2020-02-10 | Compositions comprising amino acids for use and treatment of central nervous system injuries |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009344A true MX2021009344A (es) | 2021-09-08 |
Family
ID=66286840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009344A MX2021009344A (es) | 2019-02-13 | 2020-02-10 | Composiciones con aminoacidos para el uso y tratamiento de lesiones del sistema nervioso central. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220110899A1 (es) |
| EP (1) | EP3695834B1 (es) |
| JP (1) | JP2022520720A (es) |
| KR (1) | KR20210127211A (es) |
| CN (1) | CN113825504A (es) |
| AU (1) | AU2020220889A1 (es) |
| BR (1) | BR112021015368A2 (es) |
| CA (1) | CA3129579A1 (es) |
| CL (1) | CL2021002131A1 (es) |
| EA (1) | EA202191880A1 (es) |
| ES (1) | ES2969104T3 (es) |
| IT (1) | IT201900002109A1 (es) |
| MX (1) | MX2021009344A (es) |
| PL (1) | PL3695834T3 (es) |
| SG (1) | SG11202108539XA (es) |
| WO (1) | WO2020165731A1 (es) |
| ZA (1) | ZA202105277B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201700087359A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6620850B2 (en) * | 2001-09-19 | 2003-09-16 | University Of Florida | Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors |
| CN102772407B (zh) * | 2012-08-01 | 2014-09-17 | 岳茂兴 | 一种促进神经损伤修复的药物组合物及其应用 |
| JP2020517703A (ja) * | 2017-04-28 | 2020-06-18 | アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． | アミノ酸組成物及び外傷性脳損傷の治療のためのそれらの使用 |
| IT201700087359A1 (it) * | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
| IT201700087376A1 (it) * | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
-
2019
- 2019-02-13 IT IT102019000002109A patent/IT201900002109A1/it unknown
-
2020
- 2020-02-10 CN CN202080013405.2A patent/CN113825504A/zh active Pending
- 2020-02-10 CA CA3129579A patent/CA3129579A1/en active Pending
- 2020-02-10 MX MX2021009344A patent/MX2021009344A/es unknown
- 2020-02-10 PL PL20156427.5T patent/PL3695834T3/pl unknown
- 2020-02-10 EA EA202191880A patent/EA202191880A1/ru unknown
- 2020-02-10 US US17/430,240 patent/US20220110899A1/en active Pending
- 2020-02-10 ES ES20156427T patent/ES2969104T3/es active Active
- 2020-02-10 KR KR1020217029330A patent/KR20210127211A/ko active Search and Examination
- 2020-02-10 BR BR112021015368-3A patent/BR112021015368A2/pt unknown
- 2020-02-10 AU AU2020220889A patent/AU2020220889A1/en active Pending
- 2020-02-10 JP JP2021543145A patent/JP2022520720A/ja active Pending
- 2020-02-10 WO PCT/IB2020/051027 patent/WO2020165731A1/en active Application Filing
- 2020-02-10 EP EP20156427.5A patent/EP3695834B1/en active Active
- 2020-02-10 SG SG11202108539XA patent/SG11202108539XA/en unknown
-
2021
- 2021-07-26 ZA ZA2021/05277A patent/ZA202105277B/en unknown
- 2021-08-11 CL CL2021002131A patent/CL2021002131A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210127211A (ko) | 2021-10-21 |
| IT201900002109A1 (it) | 2020-08-13 |
| CA3129579A1 (en) | 2020-08-20 |
| ES2969104T3 (es) | 2024-05-16 |
| ZA202105277B (en) | 2022-08-31 |
| EP3695834B1 (en) | 2023-10-18 |
| CL2021002131A1 (es) | 2022-03-04 |
| US20220110899A1 (en) | 2022-04-14 |
| SG11202108539XA (en) | 2021-09-29 |
| WO2020165731A1 (en) | 2020-08-20 |
| CN113825504A (zh) | 2021-12-21 |
| EP3695834A1 (en) | 2020-08-19 |
| JP2022520720A (ja) | 2022-04-01 |
| EA202191880A1 (ru) | 2021-11-23 |
| PL3695834T3 (pl) | 2024-03-11 |
| BR112021015368A2 (pt) | 2021-09-28 |
| AU2020220889A1 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500190A1 (en) | Compositions comprising amino acids for use in the treatment of mitochondrial dysfuntion-related diseases | |
| PH12020552254A1 (en) | Compositions comprising amino acids for use in the prevention and treatment of liver diseases | |
| MX2019012884A (es) | Terapia de combinacion. | |
| WO2018067217A3 (en) | COMPOSITIONS COMPRISING SHORT PEPTIDES DERIVED FROM PEDF AND USES THEREOF | |
| MX2011011459A (es) | Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos. | |
| WO2019045248A3 (ko) | 주름 개선 활성을 나타내는 펩타이드 및 이의 용도 | |
| JOP20210185A1 (ar) | مركبات هالو-آلِّيلامين واستخدامها | |
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| PH12019501424A1 (en) | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor | |
| MY187022A (en) | Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy | |
| PH12020500189A1 (en) | Compositions comprising amino acids for use in the treatment of mitochondrial dysfuntion-related diseases | |
| MX2018008545A (es) | Composicion antibacteriana y metodo para tratar infecciones por estafilococos con la composicion antibacteriana. | |
| MX2021009344A (es) | Composiciones con aminoacidos para el uso y tratamiento de lesiones del sistema nervioso central. | |
| MX2021015652A (es) | Nuevo derivado del acido aminoalcanoico que contiene un grupo bifenilo y una composicion farmaceutica antifungica que comprende el mismo. | |
| MX2022008096A (es) | Composiciones que comprenden aminoacidos para su uso en la prevencion y tratamiento de los efectos secundarios de la quimioterapia. | |
| WO2011086507A8 (en) | "compositions comprising amino acids for prevention and/or treatment of renal disorders" | |
| MX2022008095A (es) | Composiciones que comprenden aminoacidos para la prevencion y/o el tratamiento del cancer. | |
| NZ728962A (en) | Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia | |
| WO2020117516A8 (en) | Use of polycarboxylic acid compounds for the treatment of fibrous amino acid based substrates, especially hair | |
| NZ723300A (en) | Compositions for the prevention and/or treatment of pathologies associated with alpha-glucosidase | |
| WO2012015910A3 (en) | Use of adnf polypeptides for treating neurodegenerative diseases | |
| MX2019001320A (es) | Composicion y uso de un peptido. | |
| MX2017016720A (es) | Composición farmacéutica que contiene un analgésico de tipo opioide en combinación con un análogo del ácido g-aminobutírico (gaba). | |
| MX2020013639A (es) | Composicion farmaceutica para la prevencion de mastitis bovina. | |
| SG11201804902UA (en) | A composition for improving memory, learning ability, and cognitive ability |